Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ
Publikation: Beitrag in Fachzeitschrift › Forschungsartikel › Beigetragen › Begutachtung
Beitragende
Abstract
BACKGROUND: Maximum tumor resection improves overall survival (OS) in patients with glioblastoma. The extent of resection (EOR) is historically dichotomized. The RANO resect group recently proposed criteria for volumetry-based EOR assessment in patients that were treated according to Stupp´s protocol. The purpose of this study was (1) to investigate the prognostic value of EOR in patients receiving combined chemotherapy with lomustine (CCNU)/temozolomide (TMZ), and (2) to analyse the prognostic performance of binary EOR assessment compared to volumetric assessment.
METHODS: 78 patients with newly diagnosed MGMT-methylated GBM undergoing tumor resection followed by radiochemotherapy with CCNU/TMZ were included in this study. Residual contrast-enhancing (CE) tumor volume after the first resection was measured and its influence on OS and PFS was analysed using uni- and multivariable Cox regression analysis as well as two-sided log rank test. Patients were divided into RTV ≤1 cm³, >1 cm³ - ≤5 cm³ and >5 cm³ following the proposed criteria of the RANO resect group.
RESULTS: Prolonged OS was associated with age <60 years, low RTV, and gross total resection (GTR). Residual tumor volume (RTV) had a superior prognostic value compared to binary EOR assessment. Patients with total or near total resection of CE tumor (≤1 cm³ RTV) showed prolonged OS (median 54.4 months, 95% CI 46.94-not reached), with a 5-year survival rate of 49%.
CONCLUSION: Low RTV is associated with increased survival in glioblastoma patients undergoing radiochemotherapy with CCNU/TMZ. This study demonstrates the applicability of the recently proposed RANO resect criteria in this subgroup of patients.
Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 557-566 |
| Seitenumfang | 10 |
| Fachzeitschrift | Neuro-oncology |
| Jahrgang | 27 |
| Ausgabenummer | 2 |
| Frühes Online-Datum | 1 Okt. 2024 |
| Publikationsstatus | Veröffentlicht - 1 Feb. 2025 |
| Peer-Review-Status | Ja |
Externe IDs
| unpaywall | 10.1093/neuonc/noae205 |
|---|---|
| Scopus | 85217850045 |
| Mendeley | f712b0ff-e420-379b-b44c-10410374e4e5 |
Schlagworte
Schlagwörter
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Brain Neoplasms/mortality, Chemoradiotherapy/mortality, DNA Methylation, DNA Modification Methylases/genetics, DNA Repair Enzymes, Female, Follow-Up Studies, Glioblastoma/mortality, Humans, Lomustine/administration & dosage, Male, Middle Aged, Neoplasm, Residual/mortality, Prognosis, Retrospective Studies, Survival Rate, Temozolomide/therapeutic use, Young Adult